Isomorphic Labs Secures $5 Billion in Series C Funding to Advance AI Drug Discovery
Isomorphic Labs, the AI drug-discovery spin-off from Google DeepMind, has raised $5 billion in a Series C funding round. Co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and existing backers like Alphabet's GV and CapitalG, the capital is intended to transition the company's drug candidates into clinical trials. The company utilizes an AI design engine built upon DeepMind’s AlphaFold technology to simulate complex chemical interactions. Having already reported positive preclinical results in oncology and immunology, Isomorphic Labs aims to expand its therapeutic reach and further develop its simulation models. The firm has established significant partnerships with major pharmaceutical companies including Eli Lilly, Novartis, and Johnson & Johnson.
Coverage
- Isomorphic Labs Secures $5 Billion in Series C Funding to Advance AI Drug Discovery
- Science Corporation Secures $400 Million Series D Funding at $3.5 Billion Valuation
- Genesis AI Secures $500 Million Series A to Advance Dexterous Humanoid Robotics
- Genesis AI Secures $500 Million Series A Funding at $3.5 Billion Valuation